Biontech SE (BNTX) Q4 2025 Earnings Call Transcript
BioNTech’s Q4 2024 earnings call highlighted a strategic pivot toward oncology, emphasizing the advancement of its bispecific antibody BNT327 and the recent acquisition of Biotheus to secure Chinese manufacturing and development capabilities. The company reported positive Phase 2 data for its off‑the‑shelf FixVac melanoma vaccine and robust immune responses from the personalized mRNA therapy autogene cevumeran, though efficacy signals remain modest. BioNTech also confirmed it retained a leading share of the global COVID‑19 vaccine market while outlining a data‑rich 2025 pipeline focused on adjuvant settings and combination regimens.
Aged Grandmothers Pass Metabolic Shifts to Grand‑Offspring Oocytes
Intergenerational Transmission of Metabolic Changes in Oocytes From Aged Mice 👉 “ Our findings indicate a remodelling of lipid homeostasis in oocytes of female mice derived from AMA great-grandmothers and highlight the need to take a closer look at the inheritance...
PCSK9 Drives Vascular Aging, Offers New Therapeutic Targets
PCSK9 in Vascular Aging and Age-Related Diseases Comprehensive summary of PCSK9's regulatory functions in vascular aging, highlighting potential therapeutic targets for combating age-related cardiovascular diseases. https://t.co/uo3PaSJLCb https://t.co/w8UZgIduPV
Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Transcript
Biogen reported full‑year 2025 non‑GAAP diluted EPS of $15.28 and $9.9 billion in revenue, a modest 2% YoY increase. Growth‑product sales surged 19% to $3.3 billion, driven by VUMERITY, SKYCLARIS, ZERZUVE and CALSADI, while legacy MS revenues are projected to fall mid‑teens...
China’s GM Crops Remain Silent, Limited to Feed
Genetically modified crops are the dog that never barks in China. People are wary and there's very little of it outside animal feed. The next FYP is ambiguous. https://t.co/ixkR3lGCCI
Mpox Immune Test Validated During Rwandan Outbreak
Researchers from the University of Birmingham, Rwanda Biomedical Centre and the University of Rwanda have validated an IgG ELISA assay for mpox antibodies during the clade 1b outbreak in Rwanda. The MpoxCARE test, built on four key antibody signatures, demonstrated high...
Hong Kong: Tech Centre Fosters AI-Driven Healthcare Innovation
The Hong Kong Productivity Council has opened the Future Life and Health Tech Centre, a research‑development hub designed to fast‑track AI‑driven innovations across medical technology, biotechnology, functional foods and modernised traditional Chinese medicine. The facility offers an end‑to‑end platform that...
Hidden Blood Mutations Drive Severe Inflammatory Bowel Disease, but a New Treatment Target Is in Sight
Indiana University researchers linked clonal hematopoiesis of indeterminate potential (CHIP) to heightened severity of inflammatory bowel disease. Analysis of UK Biobank and All of Us data showed women with DNMT3A mutations and younger individuals with TET2 mutations face higher Crohn’s...
Gene Edit Makes Probiotic Safer for Immunocompromised Patients
An international team genetically deleted the ENA1 gene from Saccharomyces boulardii, a common probiotic yeast. In immunosuppressed mice, the ENA1‑deficient strain showed no mortality, raising survival from 30‑40% to 100% compared with wild‑type isolates. The edit also reduced osmotic stress...
Stay or Stray? Why some Gut Microbes Persist After Fecal Transplants
Researchers at King's College London identified genetic markers that determine whether donor microbes persist after fecal microbiota transplantation (FMT). By tracking biosynthetic gene clusters in 86 healthy adults over a year, they distinguished stable clusters that remain long‑term from transient...
Roche’s Giredestrant Miss Refines Treatment Settings for Oral SERDs
Roche’s oral selective estrogen receptor degrader (SERD) giredestrant failed to meet its primary endpoint in a late‑stage Phase III trial, but the data revealed meaningful activity in specific patient subgroups, particularly those with ESR1 mutations. The miss prompted Roche to...
AI Predicts Asymmetric Cross‑coupling, Slashing Lab Time and Cost
A new AI-driven workflow predicts the outcomes of asymmetric cross-coupling reactions, enabling chemists to efficiently identify optimal molecular structures while significantly reducing laboratory time and costs. drugdiscovery
Vertex Kidney Disease Drug Hits Mark in Late-Stage Study
Vertex Pharmaceuticals announced that its experimental IgA nephropathy drug povetacicept met primary and key secondary endpoints in a Phase 3 trial, cutting urine protein by roughly 50% versus placebo after 36 weeks. The interim results also showed reductions in abnormal antibodies...
CRISPR-Based Technique Unlocks Healing Power of Mitochondria for Heart Failure Therapy
Researchers at Rice University and Baylor College of Medicine used a non‑editing CRISPR system to activate the PPARGC1A gene, boosting mitochondrial production in human cardiomyocytes. The technique safely increased cellular energy output, as shown by higher oxygen consumption in cell...
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB Biotherapeutics announced full‑year 2025 results, highlighting the launch of its registrational Phase 2b SAFEGUARD trial for SAB‑142 and the completion of a $175 million oversubscribed private placement. Phase 1 data demonstrated a favorable safety profile, no serum sickness and low immunogenicity across...
Accrufer Becomes First FDA-Approved Prescription Iron Therapy for Children 10+
Shield Therapeutics announced that the FDA has approved Accrufer, its ferric maltol oral iron formulation, for children ages 10 and older, making it the first prescription oral iron therapy for this age group. The approval expands the drug’s label beyond...
New Technology Unlocks More Autism Gene Varients
Researchers at UC San Diego used long‑read whole‑genome sequencing (LR‑WGS) on 267 autism families, uncovering 33% more structural variants and 38% more tandem repeats than short‑read methods. By pairing the genomic data with DNA‑methylation profiles, they could directly observe how...
De‑risking Synthetic Biology: From Lab to Market
What does it actually take to bring a biological product to market? For more than 20 years, Ingenza Ltd has helped teams avoid the most common failure points in synthetic biology. Freedom to operate issues. Low productivity. Fragile processes. Late CMC...
APS BioGroup, Inc - 04/05/2018
The U.S. Food and Drug Administration issued a warning‑letter close‑out to APS BioGroup, Inc. on April 5, 2018, confirming that the company’s corrective actions addressing the July 2017 warning letter were satisfactory. The agency stressed that this closure does not relieve APS BioGroup...
James Findling - 598944 - 12/31/2019
The FDA issued a Warning Letter to Dr. James Findling after a 2019 inspection revealed serious protocol violations in a clinical trial of an investigational drug. The investigator randomized two subjects who had exceeded permitted dose levels and failed to...
Modular Cleanroom Supports Scale-Up of Cosmetic Microneedle Production
CipherX, a biotech start‑up specializing in microneedle platforms, partnered with Connect 2 Cleanrooms to install a 12 m² soft‑wall cleanroom for pilot production. The modular unit, validated to ISO 14644 class 7, was delivered and fully operational within 48 hours. Its PVC curtains, steel framing and...
New $8M Funding Enables Aging Biomarker Trials
A much needed effort that @Danbelsky and I have now been funded for to support the FAST initiative ($8 million over 18 months): https://t.co/aZsaZuEpoo The goal of this is to provide a set of biomarkers that will tell a person if...
FDA Slashes Advisory Panels, Threatening Drug Safety Oversight
I've covered most of the big controversies the FDA has faced over the past 25 years: Vioxx, drug-coated stents, and Aduhelm all spring to mind. In all of these cases, the FDA's advisory panel system, in which the agency calls together...
ORN0829
Taisho Pharmaceutical’s vornorexant (TS‑142), marketed as Vorzzz®, received Japanese regulatory approval in August 2025 as a dual orexin‑1/2 receptor antagonist for insomnia. The drug distinguishes itself from existing DORAs through rapid absorption and a short elimination half‑life, aiming to minimize...
An Emerging Longevity Supplement May Accelerate Cancer Growth, Scientists Say
Researchers at Tokyo University of Science discovered that polyamines, especially spermidine—a compound touted for longevity—can accelerate the growth of cancer cells. Laboratory experiments on cervical and breast cancer lines showed polyamines promote aerobic glycolysis and increase the oncogenic protein eIF5A2....
Foundation Models Set to Transform Drug Discovery
Would you like to hear an opinion on how the future of drug discovery will look like as foundation models become more capable in drug discovery tasks? Check out our dialogue and the first pilot with the foundation model genius @ramin_m_h...
Unlocking Hidden Pocket on a Billion‑dollar Drug Target
Researchers led by Harvard chemist Christina Woo have mapped a previously unknown allosteric pocket on cereblon, the E3 ligase that underpins billions of dollars in cancer‑drug activity. The study shows that binding a small molecule to this hidden site can...
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie announced top‑line Phase 1 multiple ascending‑dose data for its amylin analog ABBV‑295, showing 7.75‑9.79% weight loss after 12 weeks of treatment. The long‑acting compound was administered every other week then monthly, with a favorable tolerability profile and no serious adverse...
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China
AbbVie and its partner Gubra released Phase 2 data on a long‑acting amylin analogue that produced significant weight loss in obese participants, with reductions approaching double‑digit percentages and a clean safety signal. The study highlighted dose‑responsive efficacy and tolerability, positioning the...
Retinal Implants Let Blind See, BCI Future Looms
Max Hodak (@maxhodak_) is the co-founder of Neuralink and founder of @ScienceCorp_, a company building brain-computer interfaces that can restore sight. Science has developed a tiny retinal implant that stimulates cells in the eye to help blind patients see again. More...
Why Simulating an Entire Cell Cycle Took Years, Multiple GPUs and Six Days per Run
University of Illinois researchers led by Zan Luthey‑Schulten have built a three‑dimensional kinetic model of the minimal bacterium JCVI‑syn3A that simulates an entire 105‑minute cell cycle. By assigning DNA replication to a dedicated GPU and running other cellular dynamics on...
GLP-1 Drugs Modulate Gene Expression via MED14 Phosphorylation
Stable GLP‑1 receptor agonists such as Exendin‑4 and Ozempic improve beta‑cell viability by modulating gene expression. Researchers at the Salk Institute discovered that these drugs induce phosphorylation of Med14, a core subunit of the Mediator transcription complex. Phosphorylated Med14 enables...
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Regeneron’s Chinese partner Hansoh announced that its dual GLP‑1/GIPR agonist olatorepatide achieved a 19% mean weight loss in a Phase 3 trial of 604 obese or overweight adults, meeting both co‑primary endpoints. The study reported lower gastrointestinal adverse events compared with...
Bristol Myers Says Second CELMoD Succeeds in Phase 3
Bristol Myers Squibb announced that its oral CELMoD candidate mezigdomide met primary endpoints in the Phase 3 SUCCESSOR‑2 trial for relapsed or refractory multiple myeloma. The open‑label study showed a statistically significant improvement in progression‑free survival compared with the current standard...
Medidata, CRIO Boost Clinical Trials with Integration
Medidata, a Dassault Systèmes brand, has partnered with eSource specialist CRIO to automate clinical data flow from site systems into the Medidata Platform. The plug‑and‑play integration now serves over 2,500 research sites in roughly 30 countries, delivering near‑100% data accuracy and...
Harnessing Immune System: New Frontiers in Cancer Therapy
The new Huberman Lab episode is out: Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson 0:00 Alex Marson 2:21 Diseases & Current Biological Landscape; AI & Computational Tools 5:56 Immune System, Innate vs Adaptive Immune System 10:55 Thymus, T...
AI‑Driven Lab Loop Cuts Protein Cost 40%
OpenAI ran 86,000 experiments in 2 days. AI is talking to robotic labs in a tight loop. Result: a protein synthesized at 40% lower cost. This is the new scientific method.
Carbios Under Pressure: Financing Struggles, China Expansion, and a Growing Legal Dispute
Carbios, once a flagship of France’s industrial biotech, has seen its enzymatic PET recycling ambitions hampered by financing gaps, a delayed Longlaville plant and a costly reorganisation. The company’s cash fell to €72 million by mid‑2025, prompting a 40 % cut in...
IPV Doesn’t Block Infection, but Stops Paralytic Polio
Actually he has it a bit backwards, those vaccinated with IPV can still acquire poliovirus and shed virus, but it prevents the virus from entering the bloodstream + protects almost 100% paralytic polio, just like the Covid vaccine protects 80-90%...
Vertex Drug Cuts Kidney Disease Marker in Late-Stage Trial
Vertex $VRTX says its drug successfully reduced marker of kidney disease in late-stage trial https://t.co/TbEkcHVYBB via @Jasonmmast
How Does Early Pregnancy Lower Breast Cancer Risk? Odd Cells Could Offer Clues
Researchers reported in Nature Communications that early pregnancy prevents the accumulation of a novel hybrid mammary cell type in mice. These cells, which produce the inflammatory cytokine IL33, increase with age in never‑pregnant females and are linked to tissue changes...
Bristol Myers Reports Positive Results for Next‑Gen Blood Cancer Drug
Bristol Myers claims success in study of another next-gen blood cancer drug https://t.co/fqPbZ2Szv8 by @gwendolynawu $BMY
New Study Examines Psychedelic Use–Schizophrenia Connection
Exciting & important new study from my lab. Have you ever wondered how strong that alleged connection is between psychedelic use and #Schizophrenia? This project aims to point the telescope there & give it a focused look. Please share widely. @AlexaM_Molinaro...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule...
FDA Draft Guidance Streamlines Low‑Cost Biosimilar Approval
New FDA draft guidance outlines important streamlining of path to getting low-cost biosimilars to the market - could reduce cost of pharmacokinetic studies and allow ex-U.S. comparitor products to be used for proving biosimilarity to U.S.-licensed drugs https://t.co/ErjNOga0qo
Combat Aging Now: Common Longevity Concerns Overstated
Why is it vital for humanity to fight aging? Why are common longevity worries not big problems? My new review: https://t.co/tIcXYBFE7U a preprint of a book chapter for the upcoming radical longevity book that many in the field have contributed to. https://t.co/NFTYSMALzD
Bristol Myers Squibb Announces Positive Phase 3 Results From the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple...
Bristol Myers Squibb reported positive interim Phase 3 results from the SUCCESSOR‑2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) significantly extended progression‑free survival versus carfilzomib‑dexamethasone alone in relapsed or refractory multiple myeloma. The trial marks the first...
UniQure Sparks Gene Therapy Rally After Prasad Departs
UniQure leads genetic medicine biotech rally after news of Prasad’s exit https://t.co/zu1CtJfj29 by @realJacobBell $QURE $RGNX $ATRA $LXEO #GeneTherapy
Multivitamin Modestly Slows Epigenetic Aging; Cocoa Doesn’t
Just published @NatureMedicine A daily multivitamin (MVM) slowed epigenetic aging in a randomized trial after 2 years; effect was small (~2 months) and not seen with cocoa extract supplement (vitamin was Centrum Silver) https://t.co/snOMNsTzW7 https://t.co/a6MhMuRhJb
Genomics Delegation to Boston – June 2026
The Canadian Genomics Strategy Secretariat, Global Affairs Canada and Genome Canada are organizing a genomics trade mission to Boston during the first week of June 2026, coinciding with the Festival of Genomics, Biodata and Artificial Intelligence. Selected Canadian genomics firms...